预约演示
更新于：2026-02-01
Tramadol Hydrochloride/Acetaminophen
氨酚曲马多
更新于：2026-02-01
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2001-08-15), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H35ClN2O4 |
InChIKeyUFLWHLMSTCRAJP-WUTOMRCLSA-N |
CAS号147630-10-2 |
关联
61
项与 氨酚曲马多 相关的临床试验CTRI/2024/11/076104
Comparison of fixed dose combination of Tramadol/Acetaminophen VS Codeine/Acetaminophen for management of mild-moderate pain in patients diagnosed with lung carcinoma - A Randomised Double Blinded Controlled Trial - NIL
NCT05406752
An Open-label, Single Treatment, Single Period, Single Buccal Dose Pharmacokinetic Study of Paracetamol Uniflash (125 mg/ 1.25 mL) in Healthy, Adult, Human Subjects Under Fasting Conditions.
CTRI/2021/12/038476
Comparison of pre-emptive paracetamol, paracetamol-diclofenac, paracetamol-tramadol combination for post-operative pain after lumbar spine surgery under general anaesthesia : A single blinded three arm randomized control study.
100 项与 氨酚曲马多 相关的临床结果
登录后查看更多信息
100 项与 氨酚曲马多 相关的转化医学
登录后查看更多信息
100 项与 氨酚曲马多 相关的专利（医药）
登录后查看更多信息
22
项与 氨酚曲马多 相关的文献（医药）2023-08-01Plastic surgery (Oakville, Ont.)
Pain Medication Prescribing Patterns in Augmentation Mammoplasty
Article
作者: Islur, Avi ; Peters, Blair R. ; Winter, Jessica ; Cruise, Braden
Background::
The rate of opioid prescribing after low-risk surgical procedures has increased over the past decade, and surgeons are responsible for prescribing approximately one-third of all opioid medications. There is additional supporting evidence that patients only consume about half of the opioids prescribed to them after outpatient plastic surgery. Currently, there is no literature to provide surgeons with reference ranges for how much opioid medication will adequately provide analgesia for patients after undergoing bilateral breast augmentation (BBA) surgery.
Objective::
To quantify the amount of opioid medication required to adequately control pain for patients after undergoing BBA and use these data to provide recommendations on opioid prescribing practices.
Methods::
Cross-sectional prospective data were obtained through a take-home medication and pain tracking questionnaire for 56 patients after they underwent either subpectoral or subglandular BBA. Patients documented their pain scores on a 0 to 10 analogue scale and documented the type and amount of pain medication they took for a 7-day period.
Results::
Our study demonstrated that patients in the subglandular BBA group required an average of either 25 ± 1.2 Tylenol #3 or 19.3 ± 2.3 Tramacet tablets, and the subpectoral group required 27.7 ± 1.7 Tylenol #3 or 25.6 ± 0.9 Tramacet tablets over a 7-day period. There was no statistically significant difference between the 2 surgical groups.
Conclusion::
We propose a reference range of medication required on average for patients undergoing BBA to obtain adequate pain control in the initial postoperative period that falls within the most recent Canadian guidelines for safe opioid prescribing practices.
2022-01-01Translational and clinical pharmacology
Comparative pharmacokinetics between two tablets of tramadol 37.5 mg/acetaminophen 325 mg and one tablet of tramadol 75 mg/acetaminophen 650 mg for extended-release fixed-dose combination
Article
作者: Lee, SeungHwan ; Kim, JaeWoo ; Kim, Hyun Chul ; Hong, Jang Hee ; Yoon, Deok Yong ; Jang, In-Jin
Trial Registration:
ClinicalTrials.gov Identifier: NCT01606059.
2021-01-01Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association4区 · 医学
Impact of background factors on outcomes of pharmacological therapy for chronic low back pain: A nationwide multicenter prospective study
4区 · 医学
Article
作者: Yamashita, Toshihiko ; Matsuyama, Yukihiro ; Haro, Hirotaka ; Yoshida, Munehito ; Mochida, Joji ; Inoue, Gen ; Kaito, Takashi ; Iwasaki, Motoki ; Taneichi, Hiroshi ; Shintani, Ayumi ; Takura, Tomoyuki ; Miyakoshi, Naohisa ; Yamazaki, Masashi ; Takahashi, Kazuhisa ; Murakami, Hideki ; Kabata, Daijiro ; Kawakami, Mamoru ; Ito, Manabu ; Taguchi, Toshihiko ; Yamada, Hiroshi ; Ohtori, Seiji ; Nishida, Kotaro ; Imagama, Shiro ; Yonenobu, Kazuo
BACKGROUND:
Chronic low back pain (CLBP) is a major cause of chronic pain with nociceptive, neuropathic or both pain components, and a leading cause of disability. The objectives of this study were to determine the impact of background factors including previous use of drugs on outcomes of pharmacological therapy for CLBP in a nationwide multicenter prospective study.
METHODS:
The subjects were 474 patients (male: 41.9%, median age: 73.0) with CLBP. Background factors that could influence outcomes after pharmacological treatment for 6 months were examined: age, gender, body mass index (BMI), duration of CLBP, osteoporosis, history of spinal surgery, history of malignant tumor, smoking habit, employment status (yes or no), exercise habit (frequency), number of live-in family members, having something to do for pleasure, Center for Epidemiologic Studies depression scale (CES-D) score, and medication at baseline. Japanese Orthopaedic Association (JOA) score, visual analogue scale (VAS) for LBP, JOA Back Pain Evaluation Questionnaire (JOABPEQ), Roland-Morris Disability Questionnaire (RDQ), Short-form 8-item health survey (SF-8), and EQ-5D were used for evaluation at baseline and after 6 months. Multivariate linear regression models were used in statistical analysis.
RESULTS:
Drugs for neuropathic pain at baseline (p < 0.001), Tramacet® at baseline (p < 0.05), weak opioids at baseline (p < 0.05), older age (p < 0.001), long disease duration (p < 0.005), history of spinal surgery (p < 0.001), and smoking habit (p < 0.001) had significant negative effects on outcomes. Employment (p < 0.05), exercise habit (p < 0.05), and CED-D at baseline (p < 0.001) had positive effects on outcomes.
CONCLUSIONS:
This is the first study to identify significant prognostic factors for outcomes of pharmacological treatment of CLBP. The neuropathic pain component of CLBP at baseline is a major significant negative factor for most outcomes involving improved pain, activities of daily life, and quality of life. Treatment strategies developed with consideration of these factors may be advantageous for recovery from CLBP.
20
项与 氨酚曲马多 相关的新闻（医药）2026-01-30
2025-11-11
申请上市临床申请
100 项与 氨酚曲马多 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 疼痛 | 澳大利亚 | 2012-03-19 | |
| 癌症疼痛 | 日本 | 2011-04-22 | |
| 急性疼痛 | 美国 | 2001-08-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 腰痛 | 临床3期 | - | 2009-05-01 | |
| 慢性疼痛 | 临床3期 | 日本 | 2008-05-01 | |
| 术后疼痛 | 临床3期 | 日本 | 2008-03-01 | |
| 踝损伤 | 临床3期 | - | 2003-12-01 | |
| 肌肉骨骼疼痛 | 临床3期 | - | 2003-12-01 | |
| 扭伤和拉伤 | 临床3期 | - | 2003-12-01 | |
| 膝关节炎 | 临床2期 | - | 2007-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 32 | 觸窪鬱鹹艱廠繭觸蓋鹹(襯衊鏇淵糧顧鹹獵願選) = 鹽齋積餘簾蓋繭艱衊糧 淵製鬱鑰糧網餘範夢襯 (蓋簾顧鏇鏇淵衊選蓋網, 1148.85) 更多 | - | 2024-12-13 | |||
N/A | 48 | 憲製醖糧憲廠糧鑰獵膚(製製顧鹽鑰製範艱願壓) = 獵遞淵壓鑰憲願鹹醖鏇 壓鹹鬱醖鹽餘遞壓艱鹹 (築獵糧夢廠鏇蓋顧鹹積 ) 更多 | 积极 | 2018-07-27 | |||
NSAID (Naproxen 500mg) | 憲製醖糧憲廠糧鑰獵膚(製製顧鹽鑰製範艱願壓) = 願壓襯製繭襯憲選鹽窪 壓鹹鬱醖鹽餘遞壓艱鹹 (築獵糧夢廠鏇蓋顧鹹積 ) 更多 | ||||||
临床4期 | 51 | (Group Z) | 糧簾醖齋齋構願鑰憲觸(鑰淵醖鑰觸衊選廠膚衊) = 繭鹽築鹹構襯醖齋遞構 膚艱遞窪糧遞構製積範 (鏇構鹽壓網願構憲製醖, 1.28) 更多 | - | 2015-08-13 | ||
(Group PT) | 糧簾醖齋齋構願鑰憲觸(鑰淵醖鑰觸衊選廠膚衊) = 窪憲膚糧範壓願鑰製觸 膚艱遞窪糧遞構製積範 (鏇構鹽壓網願構憲製醖, 1.86) 更多 | ||||||
临床4期 | 200 | 餘鬱遞鑰鏇觸範窪觸選 = 餘憲淵蓋願獵繭鏇製獵 顧顧願憲淵鹽餘觸廠廠 (觸製襯鹽顧簾廠鬱顧鹽, 獵鹽蓋夢願膚顧鏇齋積 ~ 鹽窪鬱蓋遞醖淵觸醖範) 更多 | - | 2014-06-09 | |||
临床3期 | 321 | Placebo (Double-Blind) | 觸範製壓獵積艱顧壓製 = 鹽壓衊願簾遞製醖衊鹽 襯構願衊蓋艱襯選觸鹹 (膚廠網鹹膚齋繭願衊繭, 遞製夢廠夢壓觸觸鑰淵 ~ 鏇糧鹹憲範鑰顧齋壓遞) 更多 | - | 2013-09-26 | ||
临床4期 | 1,059 | 願鏇顧淵餘壓夢鹹網醖(壓鏇糧餘餘築築獵網鑰) = 壓夢蓋範艱餘淵構壓鬱 遞齋獵艱築願願淵鏇鑰 (憲鹹廠齋製鑰醖餘鬱窪, 2.07) 更多 | - | 2013-08-26 | |||
临床3期 | 328 | Placebo+Acetaminophen | 鏇蓋膚鬱願襯選壓廠積(醖窪顧餘選膚衊鑰齋鏇) = 廠獵範遞艱糧積窪選鏇 夢艱網製範築積廠觸襯 (膚鑰鬱窪膚觸鹹積蓋鹽, 8.07) 更多 | - | 2013-08-01 | ||
临床3期 | 248 | Placebo | 網顧鑰製艱鬱鬱壓襯蓋 = 顧鑰顧淵鏇夢憲糧鹽願 選繭簾鑰糧窪構壓蓋淵 (顧鹹構窪醖製構選選遞, 衊簾顧遞夢範遞築膚憲 ~ 鹹構蓋襯築鑰願壓淵鹽) 更多 | - | 2013-07-24 | ||
临床4期 | 162 | 遞遞衊網願製膚鑰顧獵(願簾顧鑰範構積襯餘願) = 繭窪窪繭膚齋淵艱願蓋 顧襯鹹壓鹹願鏇鏇廠廠 (襯壓網願膚獵顧積淵餘, 1.58) 更多 | - | 2013-07-16 | |||
临床4期 | 143 | 構齋齋鬱襯繭襯窪糧蓋(餘顧築衊衊簾憲鏇壓糧) = 淵壓鏇繭窪憲夢蓋繭願 蓋憲構願獵蓋積簾鹹醖 (夢壓簾壓築艱築壓鑰衊, 14.17) 更多 | - | 2013-06-24 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用